Trial Profile
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 11 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 14 Apr 2023 According to a Dana Farber Cancer Institute media release, this study was funded by Genentech and analysis of circulating tumor DNA was done in collaboration with Predicine, Inc.
- 14 Apr 2023 Results presented in a Dana Farber Cancer Institute media release.